These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 20113148)

  • 1. Galantamine for Alzheimer's disease.
    Prvulovic D; Hampel H; Pantel J
    Expert Opin Drug Metab Toxicol; 2010 Mar; 6(3):345-54. PubMed ID: 20113148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Galantamine: a novel cholinergic agent for Alzheimer's disease].
    Olazarán J; García G
    Neurologia; 2002 Oct; 17(8):429-36. PubMed ID: 12396973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galantamine: a review of its use in Alzheimer's disease and vascular dementia.
    Corey-Bloom J
    Int J Clin Pract; 2003 Apr; 57(3):219-23. PubMed ID: 12723727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on Alzheimer drugs (galantamine).
    Raskind MA
    Neurologist; 2003 Sep; 9(5):235-40. PubMed ID: 12971834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW; Yik PY; Mok W; Chung CP
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease.
    Prescrire Int; 2001 Dec; 10(56):180-1. PubMed ID: 11824442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.
    Bullock R; Dengiz A
    Int J Clin Pract; 2005 Jul; 59(7):817-22. PubMed ID: 15963209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinesterase inhibitors in the treatment of dementia.
    Ellis JM
    J Am Osteopath Assoc; 2005 Mar; 105(3):145-58. PubMed ID: 15863734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug therapy of dementia in elderly patients. A review.
    Olsen CE; Poulsen HD; Lublin HK
    Nord J Psychiatry; 2005; 59(2):71-7. PubMed ID: 16195103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
    Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
    Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
    Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
    Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Realistic expectations for treatment success in Alzheimer's disease.
    Geldmacher DS; Frolich L; Doody RS; Erkinjuntti T; Vellas B; Jones RW; Banerjee S; Lin P; Sano M
    J Nutr Health Aging; 2006; 10(5):417-29. PubMed ID: 17066215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galantamine in Alzheimer's disease.
    Razay G; Wilcock GK
    Expert Rev Neurother; 2008 Jan; 8(1):9-17. PubMed ID: 18088197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Observational study on safety, tolerability and effectiveness of galantamine in patients with mild to moderately severe Alzheimer's disease].
    Blesa R; García Ribas G; Galdós L; Olascoaga J; Amer G; Marey López J; Barquero M; Marsall C; Ezpeleta D
    Neurologia; 2006; 21(6):289-96. PubMed ID: 16799903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
    Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
    J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of galantamine in patients with mild Alzheimer's disease.
    Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
    Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
    Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
    Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.